Skip to main content
Premium Trial:

Request an Annual Quote

CambridgeSoft Raises $21M, Names New VP

NEW YORK (GenomeWeb News) – Life science informatics developer CambridgeSoft said today that it has completed a $21 million private equity investment by Goldman Sachs.
 
In connection with the offering, Raheel Zia, a vice president at Goldman Sachs Principal Investment Area, will join CambridgeSoft's board of directors.
 
In addition, CambridgeSoft said that it has hired Michael Stapleton as vice president of corporate development, “with responsibilities for supporting the company's merger and acquisitions activities.”
 
Stapleton previously served as chief operating officer at Accelrys, where he was responsible for integrating Molecular Simulations, Synopsys, Oxford Molecular Group, and Genetics Computer Group under the Accelrys umbrella.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.